Greenwich LifeSciences, Inc.

GLSI Healthcare Biotechnology

In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

14.55 0.77 −5.03%
Market cap
$224.9M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(566.73%) (3,068.35%) (676.66%) (986.31%)
ROA
(421.74%) (376.92%) (336.00%) (374.46%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(929.56%) (5,480.80%) (422.57%) (720.90%)
Free Cash Flow per Share
(0.63) (0.73) (0.88) (0.85)
Free Cash Flow
(8.59) (9.91) (12.78) (12.49)
Other line items

Show all line items

Columns are period end dates